The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus vandetanib changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
The review found no eligible studies for this question.
Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).
Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
It is very uncertain whether summary of findings table (subcomparison 4): targeted therapy agent… changes toxicity compared with control intervention alone (very low certainty).
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in studies with gastric cancer participants in addition to eligible… compared with gastric carcinoma; GRADE not reported.
It is very uncertain whether summary of findings table (sensitivity analysis): interventions… changes sensitivity analysis, meta‐regression analysis, first part compared with gastric carcinoma (very low certainty).
Summary of findings table (sensitivity analysis): interventions… led to lower sensitivity analysis, only esophageal and GE‐junction cancer… compared with gastric carcinoma; GRADE not reported.
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in sensitivity analysis, only gastric cancer participants compared with gastric carcinoma; GRADE not reported.
Summary of findings table (sensitivity analysis): interventions… probably leads to lower sensitivity analysis, meta‐regression analysis, second part compared with gastric carcinoma (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).